| Identification | Back Directory | [Name]
H-GLY-TYR-PRO-GLY-GLN-VAL-OH | [CAS]
225779-44-2 | [Synonyms]
PAR 4 (1-6)
PAR-4 (1-6) (HUMAN)
GLY-TYR-PRO-GLY-GLN-VAL
H-GLY-TYR-PRO-GLY-GLN-VAL-OH
GYPGQV trifluoroacetate salt
PAR-4 AGONIST PEPTIDE (GYPGQV), HUMAN
H-GLY-TYR-PRO-GLY-GLN-VAL-OH USP/EP/BP
Gly-Tyr-Pro-Gly-Gln-Val trifluoroacetate salt
Glycyl-L-tyrosyl-L-prolylglycyl-L-glutaminyl-L-valine
L-Valine, glycyl-L-tyrosyl-L-prolylglycyl-L-glutaminyl-
PROTEINASE ACTIVATED RECEPTOR 4 AGONIST PEPTIDE (GYPGQV), HUMAN
Glycyl-L-tyrosyl-L-prolyl-glycyl-L-glutaminyl-L-valine trifluoroacetate salt
PAR-4 (1-6) (human) trifluoroacetate salt H-Gly-Tyr-Pro-Gly-Gln-Val-OH trifluoroacetate salt
GYPGQV, Coagulation Factor II Receptor-Like 3 (1-6) (huMan), Proteinase Activated Receptor 4 (1-6) (huMan), ThroMbin Receptor-Like 3 (1-6) (huMan) | [Molecular Formula]
C28H41N7O9 | [MDL Number]
MFCD02181012 | [MOL File]
225779-44-2.mol | [Molecular Weight]
619.67 |
| Hazard Information | Back Directory | [Description]
PAR4 (1-6) is a peptide agonist of proteinase-activated receptor 4 (PAR4) that corresponds to residues 1-6 of the amino terminal tethered ligand sequence of human PAR4 and residues 48-53 of the full-length sequence. It activates PAR4 and the cleavage site mutant PAR4R47A when used at a concentration of 500 μM. PAR4 (1-6) induces platelet aggregation of isolated washed human platelets when used at a concentration of 1 mM but does not affect clotting time induced by factor VIIa, soluble tissue factor, and collagen in an ex vivo coagulation assay. | [Uses]
PAR 4 (1-6) human, a hexapeptide, is a fragment of protease-activated receptor 4 (PAR4). PAR 4 (1-6) TFA acts as a PAR4-specific agonist[1]. | [References]
[1] H Andersen, et al. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11189-93. DOI:10.1073/pnas.96.20.11189
[2] E Bretschneider, et al. Evidence for functionally active protease-activated receptor-4 (PAR-4) in human vascular smooth muscle cells. Br J Pharmacol. 2001 Apr;132(7):1441-6. DOI:10.1038/sj.bjp.0703947 |
|
|